Introduction
============

Soft tissue sarcomas of the head and neck are an uncommon heterogeneous group of malignancies ^[@ref-1]^, with the most common subtype being malignant fibrous histiocytoma ^[@ref-2],\ [@ref-3]^. Yet, undifferentiated sarcoma of the tongue represents an even rarer tumor within this heterogeneous group of sarcomas with limited treatment options. Thus far in the literature, only about 20 cases have been reported ^[@ref-4]^. At the time of writing, the underlying genetic aberrations of this rare undifferentiated soft tissue cancer of the tongue remains unknown. Here, we describe a case report of an undifferentiated sarcoma of the tongue with associated pathological analysis and whole-exome sequencing (WES) of the tumor to identify the underlying genetic changes and attempt to determine if there exists any potential druggable mutations for treatment.

Case report
===========

A 31-year-old Chinese male who had a 1-pack-year smoking history, was a non-drinker, had no significant past medical history, no exposure to radiation, no family history of carcinomas, particularly no family history of members with young onset malignancies, presented in December of 2016 with an anterior tongue mass. Patient biopsy revealed it to be an undifferentiated sarcoma. Further magnetic resonance imaging (MRI) demonstrated a lesion localized to the tongue that involved the extrinsic tongue musculature. Subsequently the patient underwent a total glossectomy with bilateral selective neck dissection levels I--III with an anterolateral thigh-free-flap reconstruction in January 2017. The pathological findings from the surgical specimen are further described below. WES analyses were performed on the fresh surgically resected tumor (tumor content, \>50%) and a paired blood sample. Adjuvant chemotherapy and radiation were recommended for this patient, but both options were declined because of concerns regarding long term toxicity and the effects on speech and swallowing. As of October 2017, the patient was disease-free with no documented recurrences on repeated MRI of the oral cavity and neck.

Pathological findings
---------------------

The tumor mass measured grossly 7 × 7 × 5.5 cm on examination following resection. On microscopic examination, the tumor was composed of mostly spindle cells arranged in short fascicles or a vague storiform pattern. Frequent mitotic figures and prominent tumoral necrosis were seen. No osseous, chondroid or rhadomyomatous differentiation was seen on haematoxylin and eosin staining ( [Figure 1](#f1){ref-type="fig"}-- [Figure 3](#f3){ref-type="fig"}). The closest margins were 2 mm and located at the postero-inferior, right and left margins.

![Sarcoma forming cellular fascicles is seen in the stroma of the tongue, focally invading the intrinsic muscle (left upper corner).\
The surface squamous epithelium shows no dysplastic field change or connection with sarcoma. (H&E stain; magnification, ×20).](f1000research-7-15650-g0000){#f1}

![Tumor necrosis (pink foci) was prominent in the undifferentiated sarcoma.\
(H&E stain; magnification, ×40).](f1000research-7-15650-g0001){#f2}

![The sarcoma tumor cells possessed enlarged, elongated, pleomorphic and hyperchromatic nuclei, distinct nucleoli and small amount of cytoplasm.\
Mitotic figures were frequently noted. No osseous, chondroid or rhadomyomatous differentiation was seen. (H&E stain; magnification, ×400).](f1000research-7-15650-g0002){#f3}

Further immunohistochemical studies showed that the tumor cells were positive for vimentin and p16; had focal weak positivity for SMA; had moderate positivity for TLE-1; and were negative for p63, EMA, AE1/AE3 antibodies, c-Kit, S100, CD31, CD34, desmin, myogenin, melan A, HMB45 antibody, ALK-1, human herpesvirus 8 (HHV8), CD99 (MIC-2) and SRY-box 10 (SOX10). Calponin was equivocal. No loss of integrase interactor 1 (INI1) staining was noted. PCR for high-risk human papillomavirus (HPV) DNA was negative. The Molecular Break-Apart FISH test for SS18 translocation was negative. Overall the pathological features demonstrated a high-grade sarcoma with no definite line of differentiation, consistent with an undifferentiated sarcoma.

Mutational profile of the patient's tumor
-----------------------------------------

WES at \>200x depth (Illumina HiSeq 4000) was performed to determine the genetic aberrations underlying this rare form of head and neck cancer. Normal DNA from the patient's blood was also subjected to WES at the same depth. Surprisingly, WES revealed only 19 non-synonymous mutations in the tumor. The very low rate of non-synonymous mutations is uncommon in HPV-negative and HPV-positive head and neck squamous cell carcinoma (HNSCC) ^[@ref-5]^, and is slightly lower than that of reported sarcomas.

The somatically mutated genes were, in the order of allele frequencies of these 19 mutational events, *POLDIP2* (DNA polymerase delta interacting protein 2), tubulin gamma complex associated protein 3 *TUBGCP3,*, mutated in colorectal cancers ( *MCC*), *TUBA3D* (tubulin alpha 3d), *DDX11* (DEAD/H-box helicase 11), *CWF19L2* (CWF19 like 2, cell cycle control), *ZNF91* (zinc finger protein 91), *RETSAT* (retinol saturase) (2 mutations), *PRR21* (proline rich 21), *TAS2R46* (taste 2 receptor member 46), *FAM186A* (family with sequence similarity 186 member A), *HEATR5A* (HEAT repeat containing 5A), *VPS4B* (vacuolar protein sorting 4 homolog B), *PRAMEF12* (PRAME family member 12), *FAM170B* (family with sequence similarity 170 member B), *BBS4* (Bardet-Biedl syndrome 4), *ARHGAP5* (Rho GTPase activating protein 5) and *ATAD3B* (ATPase family, AAA domain containing 3B) ( [Table 1](#T1){ref-type="table"}). Strikingly, based on the functional annotation of these mutated genes, five of the top seven mutated genes with high allele frequencies (\>10%) were known to be involved in DNA replication, and mitosis ( [Table 1](#T1){ref-type="table"}). This suggests that major somatic mutations of this rare tumor appear to affect DNA replication and mitosis, consistent with an aggressive phenotype. Of note, the patient's tumor carried a 93% allele frequency of the *POLDIP2* S28fs mutation, which is a hotspot mutation in multiple cancers. In addition, the *MCC* gene was also mutated in this rare tumor ( *MCC* p.G20S) at a high allele frequency of 28%, indicating its likely role as a driver event for tumorigenesis. Interestingly, the *PRR21* mutation is also found to be mutated at high frequencies in TCGA HNSCC cohort with a hotspot mutation S86Gfs\*291 and M48Tfs\*329 mutation, while in this tumor, *PRR21* mutation occurred at G114C, a position near to these two hotspot mutations in HNSCC.

###### List of the 19 non-synonymous mutations found in the undifferentiated sarcoma with their mutation type, allele frequency and potential function.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene         Chromosome\         Mutation type       Nucleotide change        Amino acid\   Allele\     Full gene name                Potential gene function
               position                                                         change        Frequency                                 
  ------------ ------------------- ------------------- ------------------------ ------------- ----------- ----------------------------- --------------------------------
  *POLDIP2*    chr17:26,684,390    Frameshift\         c.83dupG                 Ser28fs       93%         DNA polymerase delta\         DNA replication and DNA\
                                   insertion                                                              interacting protein 2         repair

  *TUBGCP3*    chr13:113,201,852   Frameshift\         c.1235\_\                Thr412\_\     50%         Tubulin gamma complex\        largely unknown, tubulin\
                                   deletion            1249delCGCGCGACTTTCCCA   Pro416del                 associated protein 3          gamma may be involved in\
                                                                                                                                        mitosis

  *MCC*        chr5:112824054      Missense            c.58G\>A                 Gly20Ser      28%         Mutated in colorectal\        negative regulator of cell\
                                                                                                          cancers                       cycle

  *TUBA3D*     chr2:132237643      Missense\           c.377C\>T                Ala126Val     15%         Tubulin alpha 3d              tubulin family, transport,\
                                   variant & splice\                                                                                    mitosis
                                   region variant                                                                                       

  *DDX11*      chr12:31237978      Missense            c.556C\>T                Arg186Trp     14%         DEAD/H-box helicase 11        putative RNA helicases

  *CWF19L2*    chr11:107325241     Missense            c.274G\>A                Glu92Lys      13%         CWF19 like 2, cell cycle\     likely in cell cycle control
                                                                                                          control                       

  *ZNF91*      chr19:23544852      Missense            c.929C\>A                Ala310Asp     11%         Zinc finger protein 91        unknown

  *RETSAT*     chr2:85570857       Missense            c.1598C\>T               Ala533Val     9%          Retinol saturase              promote adipogenesis and\
                                                                                                                                        favors normal adipocyte\
                                                                                                                                        differentiation

  *PRR21*      chr2:240982060      Missense            c.340G\>T                Gly114Cys     9%          Proline rich 21               unknown

  *FAM186A*    chr12:50746486      Missense            c.4129A\>C               Thr1377Pro    7%          Family with sequence\         unknown
                                                                                                          similarity 186 member A       

  *HEATR5A*    chr14:31792790      Missense            c.3768G\>A               Met1256Ile    7%          HEAT repeat containing 5A     unknown

  *RETSAT*     chr2:85570849       Missense            c.1606G\>A               Gly536Arg     6%          Retinol saturase              promote adipogenesis and\
                                                                                                                                        favors normal adipocyte\
                                                                                                                                        differentiation

  *VPS4B*      chr18:61060779      Missense            c.1096C\>T               Arg366Cys     6%          Vacuolar protein sorting 4\   intracellular protein\
                                                                                                          homolog B                     trafficking

  *PRAMEF12*   chr1:12835741       Missense            c.343A\>G                Ile115Val     5%          PRAME family member 12        unknown

  *FAM170B*    chr10:50340041      Missense            c.469G\>T                Ala157Ser     5%          Family with sequence\         unknown
                                                                                                          similarity 170 member B       

  *BBS4*       chr15:73023650      Missense            c.716T\>C                Ile239Thr     5%          Bardet-Biedl syndrome 4       Bardet-Biedl syndrome\
                                                                                                                                        gene family, associated\
                                                                                                                                        with severe pigmentary\
                                                                                                                                        retinopathy, obesity,\
                                                                                                                                        polydactyly, renal\
                                                                                                                                        malformation and cognitive\
                                                                                                                                        disability.

  *TAS2R46*    chr12:11214601      Missense            c.293T\>C                Leu98Pro      4%          Taste 2 receptor member 46    Taste receptor

  *ARHGAP5*    chr14:32561340      Missense            c.1465G\>A               Glu489Lys     4%          Rho GTPase activating\        Negatively regulates RHO\
                                                                                                          protein 5                     GTPases in cytoskeleton\
                                                                                                                                        changes

  *ATAD3B*     chr1:1431060        Missense            c.1810T\>C               Tyr604His     3%          ATPase family, AAA domain\    Interact with matrix nucleoid\
                                                                                                          containing 3B                 complexes
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Most strikingly, among all the somatic mutations identified in this patient, we found that recurrent somatic events of *RETSAT* ( *RETSAT* p.A533V and p.G536R mutations), a gene known to be important for the promotion of adipogenesis and normal adipocyte differentiation. It is plausible that *RETSAT* mutations may affect adipocyte adipogenesis and differentiation, related to the sarcoma features of this rare tumor.

Gene copy number analysis was also performed and a total of 221 somatic copy number alterations (CNA) events were identified ( [Figure 4](#f4){ref-type="fig"} and [Supplementary Table 1](#SF1){ref-type="other"}). The somatic CNA detected in this patient did not harbor any of these common HNSCC CNA events including losses of chr. 3p and 8p, as well as focal amplification or gains of chr. 3q26/28, 5p15, and 8q24 ^[@ref-5]^. The common CNA events in sarcomas including aberrations of the MDM2-p53 and p16-cyclin dependent kinase 4 (CDK4)-retinoblastoma-associated protein pathways, deletion of *TP53* (tumor protein p53), *CDKN2A* (cyclin dependent kinase inhibitor 2A), as well as chr. 12q13-q15 and *CDK4* amplification were also absent in this patient ^[@ref-6]^. These results suggest that this unique tumor is likely distinct from HNSCC and adult soft tissue sarcomas.

![A Circos plot showing somatic genetic variations.\
An ideogram of a normal karyotype is shown in the outermost ring. Chromosomes are segmented into contiguous bins of 1 Mb in size. The second ring from outside shows CNVs at corresponding chromosomal positions. Distinct heights of red dots indicate different inferred copy numbers. Regions that are not covered by any dots have a copy number of two. The third ring shows SNV density. Purple dots with different heights indicate SNV densities of the corresponding regions. The innermost ring shows positions of genes with non-synonymous mutations found in the undifferentiated sarcoma. CNV, copy number variation; SNV, single nucleotide variant.](f1000research-7-15650-g0003){#f4}

Multiple germline mutations in key tumor suppressor genes
---------------------------------------------------------

Given the young age of this patient, we also carefully examined potential aberrations in his germline mutational profile by WES of his blood DNA. Importantly, we found that this patient carried multiple germline mutational events of *TP53*, including a missense mutation of *TP53* p.P72R (100% allele frequency), 2 mutations at the immediate 5'-UTR, likely in the promoter region of *TP53* (c.-112G\>A; and c.-123C\>G; both with 100% allele frequencies), as well as two other intron variants with unknown effects ( [Table 2](#T2){ref-type="table"}). The *TP53* germline events likely explain the early age of onset for cancer for this patient. In addition, a 5'-UTR mutation, likely at the promoter region of *CDKN2A*, was identified (c.\*193G\>C), with an allele frequency of 100%. A *CASP8* (caspase 8) missense mutation, *CASP8* p.L14R, was also found in this patient's blood with a 46.7% allele frequency. However, the potential function of this mutation is unclear. Lastly, this patient carries as many as 23 germline variants of *NOTCH1*; however, none of these variants are non-synonymous mutations, and the effects of these variants are largely unknown. No telomerase reverse transcriptase promoter or exon mutation was found. Lastly, no germline gene copy number alterations were observed for any critical HNSCC-associated oncogenes or suppressor genes ( [Supplementary Table 2](#SF2){ref-type="other"})

###### List of germline mutations identified by gene, chromosome position, mutation type, nucleotide change, amino acid change and allele frequency.

  -----------------------------------------------------------------------------------------------------------------------
  Gene       Chromosome\           Mutation type             Nucleotide change                  Amino acid\   Allele\
             position                                                                           change        frequency
  ---------- --------------------- ------------------------- ---------------------------------- ------------- -----------
  *CASP8*    Chr. 2: 202,122,995   Missense                  c.41A\>G                           Lys14Arg      46.7

  *CASP8*    Chr. 2: 202,141,512   Intron                    c.838-38C\>T                       .             62.0

  *CASP8*    Chr. 2: 202,151,163   Intron                    c.1482-19A\>G                      .             50.4

  *CASP8*    Chr. 2: 202,152,162   3_prime_UTR               c.\*845T\>A                        .             76.9

  *CDKN2A*   Chr. 9: 21,968,199    3_prime_UTR               c.\*193G\>C                        .             100.0

  *HRAS*     Chr. 11: 534,242      Synonymous                c.81T\>C                           His27His      44.7

  *NOTCH1*   Chr. 9: 139,391,636   Synonymous                c.6555C\>T                         Asp2185Asp    99.4

  *NOTCH1*   Chr. 9: 139,396,408   Intron                    c.5473-43T\>C                      .             100.0

  *NOTCH1*   Chr. 9: 139,396,690   Intron                    c.5384+34G\>A                      .             100.0

  *NOTCH1*   Chr. 9: 139,397,707   Synonymous                c.5094C\>T                         Asp1698Asp    99.4

  *NOTCH1*   Chr. 9: 139,400,406   Intron                    c.4015-73G\>A                      .             100.0

  *NOTCH1*   Chr. 9: 139,400,904   Intron                    c.4014+75G\>A                      .             100.0

  *NOTCH1*   Chr. 9: 139,401,504   Intron                    c.3644-79C\>T                      .             85.7

  *NOTCH1*   Chr. 9: 139,402,663   Intron                    c.3325+21A\>G                      .             100.0

  *NOTCH1*   Chr. 9: 139,402,908   Intron                    c.3172-71A\>G                      .             100.0

  *NOTCH1*   Chr. 9: 139,403,240   Intron                    c.3171+81_3171+82insC              .             100.0

  *NOTCH1*   Chr. 9: 139,403,268   Intron                    c.3171+54A\>G                      .             100.0

  *NOTCH1*   Chr. 9: 139,403,554   Intron                    c.2970-31A\>G                      .             100.0

  *NOTCH1*   Chr. 9: 139,405,261   Splice_region\_& intron   c.2588-4G\>A                       .             100.0

  *NOTCH1*   Chr. 9: 139,407,452   Intron                    c.2467+21G\>A                      .             100.0

  *NOTCH1*   Chr. 9: 139,407,932   Synonymous                c.2265T\>C                         Asn755Asn     100.0

  *NOTCH1*   Chr. 9: 139,410,177   Intron                    c.1670-9A\>G                       .             100.0

  *NOTCH1*   Chr. 9: 139,410,424   Intron                    c.1669+9T\>C                       .             100.0

  *NOTCH1*   Chr. 9: 139,410,589   Intron                    c.1556-43T\>C                      .             100.0

  *NOTCH1*   Chr. 9: 139,410,679   Intron                    c.1556-133A\>G                     .             100.0

  *NOTCH1*   Chr. 9: 139,411,714   Intron                    c.1555+10A\>G                      .             100.0

  *NOTCH1*   Chr. 9: 139,411,880   Intron                    c.1442-43C\>T                      .             100.0

  *NOTCH1*   Chr. 9: 139,412,197   Splice_region\_& intron   c.1441+7C\>T                       .             100.0

  *NOTCH1*   Chr. 9: 139,418,260   Synonymous                c.312T\>C                          Asn104Asn     46.2

  *TP53*     Chr. 17: 7,578,115    Intron                    c.672+62A\>G                       .             100.0

  *TP53*     Chr. 17: 7,578,645    5_prime_UTR               c.-112G\>A                         .             100.0

  *TP53*     Chr. 17: 7,579,472    Missense                  c.215C\>G                          Pro72Arg      100.0

  *TP53*     Chr. 17: 7,579,643    Intron                    c.96+41_97-54delACCTGGAGGGCTGGGG   .             84.4

  *TP53*     Chr. 17: 7,579,801    5_prime_UTR               c.-123C\>G                         .             100.0
  -----------------------------------------------------------------------------------------------------------------------

Discussion
==========

The development of soft tissue sarcomas in the oral cavity and head and neck region in general are rare, with the development of an undifferentiated sarcoma in the oral cavity of an even lower likelihood ^[@ref-7],\ [@ref-8]^. A US population database analysis of head and neck sarcoma patients identified that the median age of adults affected was 55--59 years old, most commonly affecting the skin and soft tissues ^[@ref-2]^. This contrasts with the young age of our patient at presentation (31 years). The presence of a rare soft tissue sarcoma in a young patient provided the evidence to evaluate for germline mutations in addition to the somatic mutations, leading to the discovery of multiple germline *TP53* mutations, as well as multiple *CDKN2A*, and potentially multiple *NOTCH1* mutations of unclear functions. Notably, a *CASP8* mutation was also found in his germline. It is important to note that all these genes are known to be somatically mutated in HNSCC ^[@ref-5],\ [@ref-9]^.

Interestingly, the somatic mutational profile of this tumor was rather distinct from both HNSCC and sarcomas, with a relatively low number of non-synonymous mutations. Furthermore, unlike the genetic profile of soft tissue sarcomas, our sarcoma patient lacked the common somatic mutations in *TP53*, *PTEN* (phosphatase and tensin homolog) and *CDKN2A* ^[@ref-6],\ [@ref-10]^. Moreover, his tumor also lacked the most common somatic mutations of HNSCC, such as *TP53*, *NOTCH1*, *CKDN2A*, *PIK3CA* (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) and *FAT1* (FAT atypical cadherin 1) ^[@ref-5],\ [@ref-11],\ [@ref-12]^. This was partly contributed to by his heavy germline mutations of some of these key tumor suppressor genes, including *TP53* and *CDKN2A*, which are commonly mutated in both sarcoma and HNSCC, usually somatically. Furthermore, his germline events also carried *CASP8* and *NOTCH1* mutations, which are commonly somatically mutated in HNSCC rather than in the germline. This difference in mutation profile in conjunction with the young age of the patient led us to consider heavy germline mutations as a possible underlying cause of this rare undifferentiated sarcoma of the tongue.

Germline mutations in *TP53* are associated with familial clustering of early onset carcinomas, including pre-menopausal breast cancer, soft tissue sarcomas, adrenal cortical carcinomas or choroid plexus carcinomas, which together are classified as Li--Fraumeni syndrome based on Chompret criteria ^[@ref-13]--\ [@ref-16]^. Li--Fraumeni-like syndrome represents a subset of patients with familial clustering that do not meet the criteria for Li--Fraumeni syndrome ^[@ref-15]^. However, *de novo* germline mutations in *TP53* have been described, proven and are thought to be relatively common ^[@ref-17],\ [@ref-18]^. Our case highlights the importance of considering *TP53* mutations in early onset soft tissue sarcomas, even in those without familial histories, as this offers the potential to appropriately manage the patient and possibly the family.

The development of soft tissue sarcomas in an uncommon location in a young patient indicated the possibility of germline events, despite the lack of a family history of carcinomas at a young age. The early detection of these mutations can be useful in treating these patients, given the consideration that radiation wherever possible should be avoided to prevent the development of radiation-induced second malignancies ^[@ref-19]--\ [@ref-22]^. Regarding the surveillance for second primary cancers, full-body MRI examinations and positron emission tomography have been recommended, as opposed to exposure to radiation with computed tomography ^[@ref-19]^. This case highlights the need for vigilance and consideration of possible hereditary predisposition syndromes or *de novo* germline mutations in patients with rare tumours at a young age and with atypical genetic profiles.

Methods
=======

Tissue collection
-----------------

Tumor tissue and blood sample were collected from the patient under written informed consent according to The Joint Chinese University of Hong Kong -- New Territories East Cluster Clinical Research Ethics Committee, Hong Kong SAR (protocol number CRE-2015.396). The tumor mass was freshly frozen for DNA extraction using the QIAGEN DNeasy Blood and Tissue kit. Blood DNA was extracted from patient's buffy coat in a similar manner. DNA samples were then quantified and quality-assessed using a bioanalyzer.

Exome sequencing and variant calling
------------------------------------

Genomic DNA of the patient's tumor and buffy coat were used for WES using the Agilent SureSelect Human All Exon V5 Kit, with sequencing performed using the Illumina HiSeq 4000 platform (Macrogen, Korea) with a goal coverage of ×200 for tumor and ×100 for the blood (buffy coat) sample of the same patient.

Upon sequencing, all reads (FASTQ files) were mapped to the hg19 human reference genome assembly with [Burrows-Wheeler Alignment Tool](http://bio-bwa.sourceforge.net/) (version 0.7.12). Variant calling of single nucleotide variants (SNVs) and indels was performed using the [Genome Analysis Toolkit](https://software.broadinstitute.org/gatk/) (version v3.4.0) HaplotypeCaller pipeline. Called variants were annotated with [SnpEff](http://snpeff.sourceforge.net/) (version 4.3), the exome sequencing data have been deposited into European Nucleotide Archive (ENA) with accession number [PRJEB25783](https://www.ebi.ac.uk/ena/data/view/PRJEB25783). Somatic mutations were defined as mutations found in the tumor tissue of the patient but not in the patient's blood. All identified recurrent mutations were confirmed in [Integrative Genomics Viewer](http://software.broadinstitute.org/software/igv/) (IGV) (version 2.4) as a final check of the calling (100% accurate).

Copy number alterations (CNAs)
------------------------------

CNAs were analyzed from segmented WES data using the [Control-FREEC copy number and genotype caller](http://boevalab.com/FREEC/) (version 11.0) in both somatic and germline mode. In both modes, captured genomic regions were characterized using the [SureSelect Human All Exon V5 bed file](https://earray.chem.agilent.com/suredesign/). Somatic CNA analyses were run by referencing tumor WES data to the paired blood WES data, whereas germline CNA analysis were run by referencing blood WES data to the hg19 human genome assembly. Identified regions were annotated with [ANNOVAR](http://annovar.openbioinformatics.org/en/latest/) (version 2017-07-17) and SnpEff. Segments with CNA were manually confirmed with an IGV check. Genetic variations were visualized using [Circos](http://circos.ca/) (version 0.69) with "chromosomes_unites = 1000000".

Immunohistochemical staining
----------------------------

The patient's tumor tissue was FFPE-preserved and sectioned (5--8 µm) for immunohistochemical and H&E staining. Immunohistochemical staining was performed with the following antibodies: Melan A (M7196, Dako, Denmark), HMB34 (M0634, Dako, Denmark), ALK-1 (M7195, Dako, Denmark), HHV8 (NCL-HHV8-LNA, Novo, UK), MIC-2 (M3601, Dako, Denmark), SOX-10 (ACI3099, Biocare, USA), Calp (M3556, Dako, Denmark), INI1 (612110, DB transduction, USA), Vimentin (M0725, Dako, Denmark), p16 (805-4713, Ventana, USA), SMA (M0851, Dako, Denmark), p53 (M7001, Dako, Denmark), TLE1 (401M-16, Cell Marque, USA), p63 (M7317, Dako, Denmark), EMA (MS348, Thermo, UK), AE1/3 (M3515, Dako, Denmark), c-kit (A4502, Dako, Denmark), S100 (NCL-S100p, Leica, UK), CD31 (M0823, Dako, Denmark), CD34 (NCL-L-END, Leica, UK), Desmin (M0760, Dako, Denmark) and Myogenin (M3559, Dako, Denmark). Results were examined by an experienced pathologist for the presence or absence of the target proteins. Pictures were taken under a light microscope at ×20, ×40 and ×400 magnification.

HPV analysis
------------

The tumor cells from the formalin-fixed, paraffin-embedded sections were isolated for DNA extraction. The DNA was subjected to PCR analysis using the consensus primers GP5+/6+, as previously documented ^[@ref-23]^.

Consent
=======

Written informed consent for publication of their clinical details and accompanying images was obtained from the patient.

Data availability
=================

The exome sequencing data have been deposited into European Nucleotide Archive (ENA) with accession number [PRJEB25783](https://www.ebi.ac.uk/ena/data/view/PRJEB25783).

Supplementary material
======================

**Supplementary Table 1. Somatic copy number variations obtained from DNA taken from the patient's tumor.**

Click here for additional data file.

**Supplementary Table 2. Germline copy number variations obtained from DNA taken from the patient's blood.**

Click here for additional data file.
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A rare undifferentiated tongue sarcoma showing recurrent  *RETSAT *mutations and a loss-of-function  *POLDIP2 *mutation was presented in this case report. By showing comprehensive genetic analyses, it was interesting to identify the unique presentation of the common genes found in head and neck cancer, including TP53, CDKN2A, and NOTCH1. It is undoubtedly that the genetic profiles of this rare tongue sarcoma is different from those found in the common HNSCC because of distinct pathological background. Nonetheless, the presentations of this case different from the common sarcoma merit further confirmation. If it is really the case, it infers the possibility that the anatomical factor is presumably involved. Data related to the sarcoma of head and neck is suggested to be compared. Although this case might provide a chance to evaluate the mutual influence between the germline and somatic mutation, evidences are required to confirm whether the heavy germline mutation indeed affect the incidence of common somatic mutation found in this patient.
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